SCHEMBL23744752

SCHEMBL23744752

C[C@@H]1CN(c2cnc3cccnc3n2)C[C@H](C)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
SORD Q00796 1/20 0.40
PRKCQ Q04759 2/20 0.39
PRKCD Q05655 2/20 0.39
HTR3A P46098 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
HCRTR1 O43613 5/20 0.38
HCRTR2 O43614 5/20 0.38
EIF2AK4 Q9P2K8 1/20 0.37
HDAC1 Q13547 1/20 0.37
PDE10A Q9Y233 1/20 0.37
PTPN11 Q06124 2/20 0.36
PIM1 P11309 1/20 0.36
HCAR2 Q8TDS4 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345428 0.82 HTR3A (0.56) SORDHTR3AHRH4HCRTR1HCRTR2
SCHEMBL23744190 0.82 HTR3A (0.56) SORDHTR3AHRH4HCRTR1HCRTR2
SCHEMBL30345526 0.82 HTR3A (0.56) SORDHTR3AHRH4HCRTR1HCRTR2
SCHEMBL23744749 0.82 HTR3A (0.56) SORDHTR3AHRH4HCRTR1HCRTR2
SCHEMBL10219258 0.82 HTR3A (0.56) SORDHTR3AHRH4HCRTR1HCRTR2
SCHEMBL23744756 0.81 EIF2AK4 (0.39) DPP4DPP8DPP7SORDPRKCQ
SCHEMBL30345517 0.81 EIF2AK4 (0.39) DPP4DPP8DPP7SORDPRKCQ
SCHEMBL10508764 0.80 PDE10A (0.48) PRKCQPRKCDEIF2AK4HDAC1PDE10A
SCHEMBL23744098 0.80 PDE10A (0.48) PRKCQPRKCDEIF2AK4HDAC1PDE10A
SCHEMBL30345574 0.80 PDE10A (0.48) PRKCQPRKCDEIF2AK4HDAC1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 DPP4 711/4885DPP8 2138/4885DPP7 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.